A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.
Sadahisa Ogasawara
No relevant relationships to disclose
Tetsuhiro Chiba
No relevant relationships to disclose
Yoshihiko Ooka
No relevant relationships to disclose
Naoya Kanogawa
No relevant relationships to disclose
Tenyu Motoyama
No relevant relationships to disclose
Eiichiro Suzuki
No relevant relationships to disclose
Akinobu Tawada
No relevant relationships to disclose
Fumihiko Kanai
No relevant relationships to disclose
Osamu Yokosuka
Research Funding - Chugai Pharma